Literature DB >> 23225304

MED12 mutations occurring in benign and malignant mammalian smooth muscle tumors.

Dominique Nadine Markowski1, Sonja Huhle, Rolf Nimzyk, Göran Stenman, Thomas Löning, Jörn Bullerdiek.   

Abstract

Mutations of the mediator subcomplex 12 gene (MED12) recently have been described in a large group of uterine leiomyomas (UL) but only in a single malignant uterine smooth muscle tumor. To further address the occurrence of fibroid-type MED12 mutations in smooth muscle tumors, we have analyzed samples from 34 leiomyosarcomas (LMS), 21 UL, two extrauterine leiomyomas (EL), and 10 canine genital leiomyomas for the presence of MED12 mutations of the UL-type. Interestingly, besides UL MED12 mutations were found in one uterine LMS, one EL, and two canine vaginal leiomyomas. The results confirm the occurrence of fibroid-type MED12 mutations in malignant uterine smooth muscle tumors thus suggesting a rare but existing leiomyoma-LMS sequence. In addition, for the first time MED12 mutations are reported in smooth muscle tumors in a non-primate mammalian species.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23225304     DOI: 10.1002/gcc.22029

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  14 in total

1.  Somatic mutational analysis of MED12 exon 2 in uterine leiomyomas of Iranian women.

Authors:  Shirin Shahbazi; Neda Fatahi; Soheila Amini-Moghaddam
Journal:  Am J Cancer Res       Date:  2015-07-15       Impact factor: 6.166

2.  MED12 somatic mutations in fibroadenomas and phyllodes tumours of the breast.

Authors:  Salvatore Piscuoglio; Melissa Murray; Nicola Fusco; Caterina Marchiò; Florence L Loo; Luciano G Martelotto; Anne M Schultheis; Muzaffar Akram; Britta Weigelt; Edi Brogi; Jorge S Reis-Filho
Journal:  Histopathology       Date:  2015-05-24       Impact factor: 5.087

Review 3.  Epidemiological and genetic clues for molecular mechanisms involved in uterine leiomyoma development and growth.

Authors:  Arno E Commandeur; Aaron K Styer; Jose M Teixeira
Journal:  Hum Reprod Update       Date:  2015-07-03       Impact factor: 15.610

Review 4.  Mediator kinase module and human tumorigenesis.

Authors:  Alison D Clark; Marieke Oldenbroek; Thomas G Boyer
Journal:  Crit Rev Biochem Mol Biol       Date:  2015-07-16       Impact factor: 8.250

Review 5.  Reasons to Reconsider Risk Associated With Power Morcellation of Uterine Fibroids.

Authors:  Burkhard Helmke; Joern Bullerdiek; Carsten Holzmann; Wolfgang Kuepker; Birgit Rommel
Journal:  In Vivo       Date:  2020 Jan-Feb       Impact factor: 2.155

6.  MED12 exon 2 mutations in phyllodes tumors of the breast.

Authors:  Satoi Nagasawa; Ichiro Maeda; Takayo Fukuda; Wenwen Wu; Ryosuke Hayami; Yasuyuki Kojima; Ko-Ichiro Tsugawa; Tomohiko Ohta
Journal:  Cancer Med       Date:  2015-04-13       Impact factor: 4.452

7.  MED12 and HMGA2 mutations: two independent genetic events in uterine leiomyoma and leiomyosarcoma.

Authors:  Elizabeth Bertsch; Wenan Qiang; Qing Zhang; Margarita Espona-Fiedler; Stacy Druschitz; Yu Liu; Khush Mittal; Beihua Kong; Takeshi Kurita; Jian-Jun Wei
Journal:  Mod Pathol       Date:  2014-01-03       Impact factor: 7.842

8.  A rare coincidence of different types of driver mutations among uterine leiomyomas (UL).

Authors:  Carsten Holzmann; Dominique Nadine Markowski; Sabine Bartnitzke; Dirk Koczan; Burkhard Maria Helmke; Jörn Bullerdiek
Journal:  Mol Cytogenet       Date:  2015-10-14       Impact factor: 2.009

9.  Frequency of MED12 Mutation in Relation to Tumor and Patient's Clinical Characteristics: a Meta-analysis.

Authors:  Chao He; William Nelson; Hui Li; Ya-Dong Xu; Xue-Jiao Dai; Ying-Xiong Wang; Yu-Bin Ding; Yan-Ping Li; Tian Li
Journal:  Reprod Sci       Date:  2021-02-10       Impact factor: 3.060

10.  Molecular topography of the MED12-deleted region in smooth muscle tumors: a possible link between non-B DNA structures and hypermutability.

Authors:  Dominique Nadine Markowski; Rolf Nimzyk; Gazanfer Belge; Thomas Löning; Burkhard Maria Helmke; Jörn Bullerdiek
Journal:  Mol Cytogenet       Date:  2013-06-05       Impact factor: 2.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.